Physician profile
Abe Kaplan
NPI 1407843816
$953.14
in general payments reported to CMS, 2019-2025
13 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.63 · 2021: $195 · 2022: $224 · 2023: $259 · 2024: $61.67 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $375.61 | 2019-2025 | Rocklatan, Clareon, Simbrinza |
| Biotissue Holdings INC. | $242.36 | 2022-2023 | |
| Amgen INC. | $70.53 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $48.73 | 2022-2023 | Vyzulta |
| Apellis Pharmaceuticals, INC. | $47.79 | 2024-2025 | Syfovre |
| Abbvie INC. | $30.70 | 2025 | |
| Horizon Therapeutics Plc | $24.76 | 2021 | |
| Thea Pharma INC. | $24.49 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.31 | 2022 | |
| Beaver-Visitec International, INC. | $21.71 | 2025 | |
| Tearlab Corp | $16.27 | 2024 | Scoutpro Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.01 | 2021 | |
| Ocular Therapeutix, INC. | $12.87 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abe Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.